Endogena Therapeutics has completed enrolment of patients ahead of schedule in its Phase I/IIa clinical trial of EA-2353 to treat retinitis pigmentosa (RP).
The study, which is now in the expansion cohort stage, is evaluating the safety, tolerability, and preliminary efficacy of intravitreal EA-2353 in 14 patients with RP.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Being conducted across five sites in the US, the trial treated its first patient in July last year.
Endogena Therapeutics CEO Matthias Steger said: “Getting this far in a remarkably short time is testament to the outstanding execution of our clinical team in collaboration with InFocus Clinical Research.
“There’s a tremendous enthusiasm surrounding our trial and completing enrolment ahead of schedule has only been possible thanks to the invaluable contribution of the patients, their families, the investigators and their study staff.
“We are all driven by the hope of finding a treatment for this rare and devastating disease.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataTop line interim data from the trial is expected early next year.
A first-in-class small molecule EA-2353 follows gene-independent treatment approach showing significant advantages in RP. It selectively activates endogenous progenitor and retinal stem cells that differentiate into photoreceptors and help in restoring visual function.
